Abstract 978P
Background
The optimal treatment (Tx) strategy for aHCC pts who have progressed on frontline A/B is undefined. We evaluated 2nd line Tx patterns and clinical outcomes of aHCC pts following progression on A/B to identify factors associated with post-progression survival (PPS).
Methods
Real world patient data were retrieved from an international HCC database. PPS was from first radiographic progression on A/B to death. Kaplan-Meier median survivals and 95%CI were compared with univariate Cox-regression analysis. Univariate (UVA) and multivariate (MVA) Cox-regression analyses assessed the impact of baseline clinical factors on PPS.
Results
We identified 406 pts alive with progression on A/B. 220 continued active systemic Tx: 203 received 1 further line, 155 with tyrosine kinase inhibitors (TKIs), 45 with immunotherapy, and the remainder had missing data. Median duration of 2nd line Tx was 2.2 months (mo) (IO: 2.3 mo, TKI; 2.1). Compared to pts who received best supportive care (BSC; n=186), pts on active Tx were younger, Child Pugh class (CP) A , ECOG <2 when A/B stopped, had viral etiology, no extrahepatic disease, and had disease control during A/B. Median follow-up from A/B progression was 7.5 mo (95%CI 6.3-8.6). mPPS for all pts was 6.0 mo (95%CI 5.2-7.2). Continued active Tx was associated with prolonged mPPS compared to BSC (9.7 vs 2.0 mo; HR: 0.30; 95%CI 0.2-0.4, p<0.001). mPPS was longer with IO (11.8 mo; 95%C: 6.4-NA) than with TKIs (8.1 mo; 95%CI 6.3-10.4) or BSC (2.0 mos ;95%CI 1.5-2.9). Male sex, ECOG ≥2 at time of A/B interruption, CP B/C, portal vein tumor thrombosis (PVTT), and primary progression on A/B were associated with increased risk of death in UVA. In MVA, PVTT, ECOG ≥2 and BSC independently predicted poor PPS. Active tx was associated with longer mPPS (8.6 mo, 95%CI 6.3-13.0 vs 2.5, 95%CI 2.1-4.4; HR:0.40, 95%CI 0.28-0.58) after performing propensity score matching for confounding factors (ECOG at A/B stop, PVTT, CPS, DCR during A/B).
Conclusions
In addition to known disease related factors, continuation of systemic Tx instead of BSC following progression on A/B is independently associated with improved PPS in pts with aHCC. mPPS was nearly 1 year with IO-based Tx, suggesting a potential role for IO beyond progression after A/B.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L. Rimassa: Financial Interests, Personal, Advisory Board, Consulting and advisory role: AstraZeneca, Basilea, Bayer, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; Financial Interests, Personal, Invited Speaker, Lecture fees: AstraZeneca, Incyte, Roche, Servier; Financial Interests, Personal, Other, Travel expenses: AstraZeneca; Financial Interests, Institutional, Steering Committee Member: Exelixis, Incyte, Ipsen, Nerviano Medical Sciences, Roche; Financial Interests, Institutional, Coordinating PI, National (Italian) coordinating PI: AstraZeneca, BeiGene; Financial Interests, Institutional, Local PI: Agios, Eisai, Fibrogen, Lilly, MSD, Zymeworks; Financial Interests, Institutional, Funding: Ipsen. A. Vogel: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Böhringer Mannheim, EISAI, Incyte, Ipsen, Janssen, MSD, PierreFabre, Roche, Servier, Sirtex, Tyra, Tahio; Financial Interests, Personal, Invited Speaker: BMS, Eisai, Incyte, Ipsen, Lilly, MSD, Roche; Financial Interests, Personal, Steering Committee Member: Roche, MSD, BeiGene, Jiangsu Hengrui Medicines.. M. Kudo: Financial Interests, Personal, Invited Speaker: Eisai, Chugai, Eli Liiy, Bayer, Takeda, MSD; Financial Interests, Institutional, Research Grant: Otsuka, Sumitomo Dainippon Pharma, EA Pharma, Taiho, Eisai, AbbVie, Gilead Sciences, Takeda, GE Healthcare, Chugai. S. Ulahannan: Financial Interests, Personal, Advisory Board: array, incyte, bayer, syros, eisai, AstraZeneca; Financial Interests, Institutional, Local PI: AstraZeneca, AbbVie, adlai nortye, arqule, atreca, BI, BMS, Celgene, Ciclomed LLC, Erasca, Evelo Biosciences, Exelexis, G1 Therapeutics, GSK, IGM biosciences, Incyte, isofol, Klus pharma, Macrogenics, merck, Mersana, Oncomed, Pfizer, regeneron, Revolution Medicines, Synermore Biologics, Takeda, Tarveda Therapeutics, Tesaro, Tempest, Vigeo, Tvardi, hutch med. D.J. Pinato: Financial Interests, Personal, Advisory Board: Mina Therapeutics, EISAI, Exact Sciences, MURSLA, H3B, DaVolterra, AstraZeneca, Bayer Healthcare; Financial Interests, Personal, Invited Speaker: BMS, IPSEN, Roche; Financial Interests, Personal, Other, Editor in Chief role: Wiley; Financial Interests, Institutional, Research Grant: BMS, MSD; Non-Financial Interests, Principal Investigator: Incyte, H3B, Starpharma, Roche, Ribon Therapeutics, Turning Point Therapeutics, Apollomics; Non-Financial Interests, Other, Charity Trustee: Cancer Treatment and Research Trust. All other authors have declared no conflicts of interest.
Resources from the same session
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18